These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 19060915)

  • 1. Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.
    Rao YJ; Xi L
    Acta Pharmacol Sin; 2009 Jan; 30(1):1-24. PubMed ID: 19060915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease.
    Osadchii OE
    Cardiovasc Drugs Ther; 2007 Jun; 21(3):171-94. PubMed ID: 17373584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.
    Wallis RM; Corbin JD; Francis SH; Ellis P
    Am J Cardiol; 1999 Mar; 83(5A):3C-12C. PubMed ID: 10078537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.
    Saenz de Tejada I; Angulo J; Cuevas P; Fernández A; Moncada I; Allona A; Lledó E; Körschen HG; Niewöhner U; Haning H; Pages E; Bischoff E
    Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase inhibition and positive inotropic effects.
    Schmitz W; von der Leyen H; Meyer W; Neumann J; Scholz H
    J Cardiovasc Pharmacol; 1989; 14 Suppl 3():S11-4. PubMed ID: 2478797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.
    Kamel R; Leroy J; Vandecasteele G; Fischmeister R
    Nat Rev Cardiol; 2023 Feb; 20(2):90-108. PubMed ID: 36050457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of phosphodiesterase isoenzymes and cyclic nucleotide efflux to the regulation of cyclic GMP levels in aortic smooth muscle cells.
    Mercapide J; Santiago E; Alberdi E; Martinez-Irujo JJ
    Biochem Pharmacol; 1999 Nov; 58(10):1675-83. PubMed ID: 10535760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network.
    Zhao CY; Greenstein JL; Winslow RL
    J Mol Cell Cardiol; 2016 Feb; 91():215-27. PubMed ID: 26773602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective.
    Bobin P; Belacel-Ouari M; Bedioune I; Zhang L; Leroy J; Leblais V; Fischmeister R; Vandecasteele G
    Arch Cardiovasc Dis; 2016; 109(6-7):431-43. PubMed ID: 27184830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries--immunohistochemical distribution and functional significance.
    Waldkirch E; Uckert S; Yildirim H; Sohn M; Jonas U; Stief CG; Andersson KE; Hedlund P
    World J Urol; 2005 Dec; 23(6):405-10. PubMed ID: 16292559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use.
    Bender AT; Beavo JA
    Pharmacol Rev; 2006 Sep; 58(3):488-520. PubMed ID: 16968949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure.
    Preedy MEJ
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):401-417. PubMed ID: 32172427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig.
    Johnson WB; Katugampola S; Able S; Napier C; Harding SE
    Life Sci; 2012 Feb; 90(9-10):328-36. PubMed ID: 22261303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.
    Keravis T; Lugnier C
    Br J Pharmacol; 2012 Mar; 165(5):1288-305. PubMed ID: 22014080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.
    Zhao CY; Greenstein JL; Winslow RL
    J Mol Cell Cardiol; 2015 Nov; 88():29-38. PubMed ID: 26388264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery.
    Pauvert O; Salvail D; Rousseau E; Lugnier C; Marthan R; Savineau JP
    Biochem Pharmacol; 2002 May; 63(9):1763-72. PubMed ID: 12007579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterases and Compartmentation of cAMP and cGMP Signaling in Regulation of Cardiac Contractility in Normal and Failing Hearts.
    Calamera G; Moltzau LR; Levy FO; Andressen KW
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic nucleotide signalling compartmentation by PDEs in cultured vascular smooth muscle cells.
    Zhang L; Bouadjel K; Manoury B; Vandecasteele G; Fischmeister R; Leblais V
    Br J Pharmacol; 2019 Jun; 176(11):1780-1792. PubMed ID: 30825186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.